These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 22891207)
1. Liver injury in the elderly due to fluoroquinolones: should these drugs be avoided? Hayashi PH; Chalasani NP CMAJ; 2012 Oct; 184(14):1555-6. PubMed ID: 22891207 [No Abstract] [Full Text] [Related]
2. [Moxifloxacin and hepatic toxicity]. Franco Hidalgo S; Prieto de Paula JM; García Lorenzo R; Salado Valdivieso I Gastroenterol Hepatol; 2009 Dec; 32(10):719-20. PubMed ID: 19664854 [No Abstract] [Full Text] [Related]
3. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. Paterson JM; Mamdani MM; Manno M; Juurlink DN; CMAJ; 2012 Oct; 184(14):1565-70. PubMed ID: 22891208 [TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens. Roberts CH; Smith C; Breen R; Gadhok R; Murphy M; Aryee A; Cropley I; Bhagani S; Hopkins S; Lipman M Int J Tuberc Lung Dis; 2011 Sep; 15(9):1275-6. PubMed ID: 21943863 [No Abstract] [Full Text] [Related]
9. Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections. Prescrire Int; 2009 Oct; 18(103):206. PubMed ID: 19882787 [TBL] [Abstract][Full Text] [Related]
10. Drug Points: tachycardia associated with moxifloxacin. Siepmann M; Kirch W BMJ; 2001 Jan; 322(7277):23. PubMed ID: 11141146 [No Abstract] [Full Text] [Related]
11. Choice of baseline in parallel thorough QT studies. Graff C Drug Saf; 2013 Jun; 36(6):389-92. PubMed ID: 23620171 [No Abstract] [Full Text] [Related]
12. [Fatal acute hepatitis and cholestasis associated with liver disease]. Puerto Alonso JL; Díaz Souza P; Chamorro Mohedano J; Rojas Martín E Med Clin (Barc); 2010 Mar; 134(8):375-6. PubMed ID: 19447449 [No Abstract] [Full Text] [Related]
13. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Iannini PB Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736 [TBL] [Abstract][Full Text] [Related]
14. Tolerance of moxifloxacin-containing regimens in the treatment of tuberculosis. Fung SL; Yan SW; Chau CH; Yew WW Int J Tuberc Lung Dis; 2012 Feb; 16(2):282-3. PubMed ID: 22236937 [No Abstract] [Full Text] [Related]
15. Drug-induced immune thrombocytopenia due to moxifloxacin. Coker TJ BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23329709 [TBL] [Abstract][Full Text] [Related]
16. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study. Alshammari TM; Larrat EP; Morrill HJ; Caffrey AR; Quilliam BJ; LaPlante KL Am J Health Syst Pharm; 2014 Jan; 71(1):37-43. PubMed ID: 24352180 [TBL] [Abstract][Full Text] [Related]
17. Recurrent tendinitis after treatment with two different fluoroquinolones. Burkhardt O; Köhnlein T; Pap T; Welte T Scand J Infect Dis; 2004; 36(4):315-6. PubMed ID: 15198194 [TBL] [Abstract][Full Text] [Related]